Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Centro de Estudios en Infectogía Pediatrica
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
At least 18 years of age
Confirmed SARS-CoV-2 by RT-PCR or antigen detection in a Colombian NIH-approved laboratory
Beginning of symptoms in the past 7 days
Mild disease
Informed consent
You may not be if
Preexisting liver disease
Hypersensitivity to ivermectin
Participants in other clinical trials for therapies against COVID-19
Severe pneumonia
Pregnant or breastfeeding women
Concomitant use of warfarin, erdafitinib or quinidine
Use of ivermectin in the 5 days prior to randomization
Inability to obtain a blood sample needed to assess liver transaminases
Elevation of transaminases \>1.5 times the normal level
Participant whose first contact with the study personnel occurs between days 5 and 7 and at that time manifests significant and progressive resolution of COVID-19 related signs and symptoms
